CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 150 enrolled
Drug / intervention
Antidepressant +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00767624
NCT00767624Phase 3Completed
CompareCT.gov

Improving Depression Outcome by Adding Insomnia Therapy to Antidepressants

Stanford University·interventional·Posted Oct 7, 2008·Updated Dec 5, 2016

In Brief

A Phase 3 clinical trial evaluating Antidepressant, Desensitization Therapy for Insomnia, and 1 other intervention for Sleep Initiation and Maintenance Disorders and Depression. Completed, enrolled 150 participants across 3 sites.

Detailed Summary

The aim of the proposed three-site study is to increase the rate of full remission from major depressive disorder (MDD) at the end of 16 weeks of treatment for people who experience both major depressive disorder and insomnia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSleep Initiation and Maintenance Disorders, Depression
CountriesUnited States
CollaboratorsDuke University, University of Pittsburgh, University of Pennsylvania

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedOct 7, 2008
Enrollment StartDec 1, 2008
Primary CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.5 yearsPosted 17.7 years ago

Interventions

Antidepressantdrug

Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance

Desensitization Therapy for Insomniabehavioral

Cognitive Behavioral Therapy for Insomniabehavioral